Certara, Inc. (CERT)
NASDAQ: CERT · Real-Time Price · USD
11.33
-0.23 (-1.95%)
At close: May 28, 2025, 4:00 PM
11.15
-0.17 (-1.55%)
After-hours: May 28, 2025, 4:50 PM EDT
Certara Revenue
Certara had revenue of $106.00M in the quarter ending March 31, 2025, with 9.67% growth. This brings the company's revenue in the last twelve months to $394.50M, up 9.37% year-over-year. In the year 2024, Certara had annual revenue of $385.15M with 8.70% growth.
Revenue (ttm)
$394.50M
Revenue Growth
+9.37%
P/S Ratio
4.62
Revenue / Employee
$255,173
Employees
1,546
Market Cap
1.84B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CERT News
- 22 days ago - Certara, Inc. (CERT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Certara Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Certara to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report - Benzinga
- 6 weeks ago - Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing - GlobeNewsWire
- 6 weeks ago - Buy Certara After The FDA Announcement - Seeking Alpha
- 6 weeks ago - What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Benzinga
- 2 months ago - Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities - GlobeNewsWire